罗莫单抗对患有严重骨质疏松症和神经性厌食症的绝经前妇女的影响

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI:10.1016/j.afos.2023.10.001

Kazuki Fujimoto , Narumi Maki , Daisuke Hashiba , Toshifumi Maeyama , Ryosuke Nakagawa , Hajime Arai , Seiji Ohtori

{"title":"罗莫单抗对患有严重骨质疏松症和神经性厌食症的绝经前妇女的影响","authors":"Kazuki Fujimoto , Narumi Maki , Daisuke Hashiba , Toshifumi Maeyama , Ryosuke Nakagawa , Hajime Arai , Seiji Ohtori","doi":"10.1016/j.afos.2023.10.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>This study aims to investigate the effects of romosozumab on bone mineral density (BMD) and bone metabolism.</div></div><div><h3>Methods</h3><div>In this retrospective case series, romosozumab was administered to 5 premenopausal female patients with osteoporosis and anorexia nervosa with fragility fractures. BMD and bone turnover marker changes were investigated at 6 months and 1 year after administering romosozumab.</div></div><div><h3>Results</h3><div>BMD increased and high-turnover bone metabolism decreased 6 months and 1 year after administering romosozumab.</div></div><div><h3>Conclusions</h3><div>Romosozumab is useful for treating osteoporosis in patients with anorexia nervosa.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"9 4","pages":"Pages 137-141"},"PeriodicalIF":2.5000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of romosozumab in premenopausal women with severe osteoporosis and anorexia nervosa\",\"authors\":\"Kazuki Fujimoto , Narumi Maki , Daisuke Hashiba , Toshifumi Maeyama , Ryosuke Nakagawa , Hajime Arai , Seiji Ohtori\",\"doi\":\"10.1016/j.afos.2023.10.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>This study aims to investigate the effects of romosozumab on bone mineral density (BMD) and bone metabolism.</div></div><div><h3>Methods</h3><div>In this retrospective case series, romosozumab was administered to 5 premenopausal female patients with osteoporosis and anorexia nervosa with fragility fractures. BMD and bone turnover marker changes were investigated at 6 months and 1 year after administering romosozumab.</div></div><div><h3>Results</h3><div>BMD increased and high-turnover bone metabolism decreased 6 months and 1 year after administering romosozumab.</div></div><div><h3>Conclusions</h3><div>Romosozumab is useful for treating osteoporosis in patients with anorexia nervosa.</div></div>\",\"PeriodicalId\":19701,\"journal\":{\"name\":\"Osteoporosis and Sarcopenia\",\"volume\":\"9 4\",\"pages\":\"Pages 137-141\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Osteoporosis and Sarcopenia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405525523000687\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Osteoporosis and Sarcopenia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405525523000687","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

目的探讨romosozumab对骨密度（BMD）和骨代谢的影响。方法回顾性研究5例绝经前女性骨质疏松性神经性厌食症伴脆性骨折患者的罗莫索单抗治疗。在给予romosozumab 6个月和1年后研究BMD和骨转换标志物的变化。结果给予罗莫索单抗后6个月和1年，骨密度升高，高转换骨代谢降低。结论romosozumab治疗神经性厌食症骨质疏松症有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Effect of romosozumab in premenopausal women with severe osteoporosis and anorexia nervosa

Objectives

This study aims to investigate the effects of romosozumab on bone mineral density (BMD) and bone metabolism.

Methods

In this retrospective case series, romosozumab was administered to 5 premenopausal female patients with osteoporosis and anorexia nervosa with fragility fractures. BMD and bone turnover marker changes were investigated at 6 months and 1 year after administering romosozumab.

Results

BMD increased and high-turnover bone metabolism decreased 6 months and 1 year after administering romosozumab.

Conclusions

Romosozumab is useful for treating osteoporosis in patients with anorexia nervosa.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Osteoporosis and Sarcopenia Orthopedics, Sports Medicine and Rehabilitation, Endocrinology, Diabetes and Metabolism, Obstetrics, Gynecology and Women's Health, Geriatrics and Gerontology

自引率

5.00%

发文量

审稿时长

66 days